Graticule Asia Macro Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Graticule Asia Macro Advisors's XBI Position: Q1 2017 in Review
Graticule Asia Macro Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2017, closing a stake of 23,010 shares — an estimated $1.36M sold.
Graticule Asia Macro Advisors first reported a position in XBI in Q3 2015 and held it in 4 quarters. The position peaked at $1.36M in Q4 2016. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.
- Graticule Asia Macro Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2017 after selling out during the quarter.
- Graticule Asia Macro Advisors sold 23,010 State Street SPDR S&P Biotech ETF shares in Q1 2017, an estimated $1.36M.
- Graticule Asia Macro Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and held it in 4 quarters.
- Graticule Asia Macro Advisors's State Street SPDR S&P Biotech ETF position peaked at $1.36M in Q4 2016.
- 292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.
Based on Graticule Asia Macro Advisors's 13F filing for Q1 2017, filed 12 May 2017.